Oxaliplatin Alternatives Compared
| Oxaliplatin | Keytruda (pembrolizumab) | Opdivo (nivolumab) |
|
|---|
| Oxaliplatin | Keytruda (pembrolizumab) | Opdivo (nivolumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Colorectal Cancer. Oxaliplatin may also be used for purposes not listed in this medication guide. |
Prescription only
Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including... View more |
Prescription only
Opdivo is an immune checkpoint inhibitor that may be used to treat many different cancers including melanoma, bladder cancer, liver cancer, and lung cancer. Fatigue, skin conditions, a cough, upper... View more |
Related suggestions Colorectal Cancer
Popular comparisons
|
|||||||||||||||||||||||
| More about Oxaliplatin | More about Keytruda (pembrolizumab) | More about Opdivo (nivolumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Oxaliplatin has an average rating of 4.0 out of 10 from a total of 5 ratings on Drugs.com. 20% of reviewers reported a positive effect, while 60% reported a negative effect. |
Keytruda has an average rating of 4.9 out of 10 from a total of 249 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 49% reported a negative effect. |
Opdivo has an average rating of 5.6 out of 10 from a total of 93 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 43% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Oxaliplatin side effects |
View all Keytruda side effects |
View all Opdivo side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Oxaliplatin prices |
View all Keytruda prices |
View all Opdivo prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Eloxatin |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
391 hours |
624 hours |
640.8 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 626 drugs are known to interact with Oxaliplatin:
|
A total of 557 drugs are known to interact with Keytruda:
|
A total of 557 drugs are known to interact with Opdivo:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
N/A |
December 22, 2014 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.